BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:22 am Sale | 2023-12-31 | 13G | VIRIDIAN THERAPEUTICS INC VRDN | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -2,302,094 (Position Closed) | Filing |
| 2023-02-14 11:43 am Purchase | 2022-12-31 | 13G | VIRIDIAN THERAPEUTICS INC VRDN | BIOTECHNOLOGY VALUE FUND L P | 2,302,094 5.600% | 99,779 (+4.53%) | Filing |
| 2022-02-14 1:51 pm Sale | 2021-12-31 | 13G | VIRIDIAN THERAPEUTICS INC VRDN | BIOTECHNOLOGY VALUE FUND L P | 2,202,315 9.990% | -5,381,904 (-70.96%) | Filing |